护城河对比

The FY2026 10-K competition section describes tool-level qualification lock-in as the structural fact of the industry: 'semiconductor manufacturers must make a substantial investment to qualify and integrate new capital equipment into semiconductor production lines. As a result, once a semiconductor manufacturer has selected a particular supplier's equipment and qualified it for production, the manufacturer generally maintains that selection for that specific production application and technology node as long as the supplier's products demonstrate performance to specification in the installed base.' The filing then sizes what that incumbency is worth: of 23,232,690 thousand dollars of FY2026 revenue, 8,347,202 thousand - about 36% - was customer-support-related revenue and other, which the same document defines as 'sales of customer services, spares, upgrades, and non-leading-edge equipment' sold back into the installed base. A qualified position plus a third of revenue annuitised against it is a durable barrier rather than a cyclical one.

来源：sec.gov

The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion.

来源：sec.gov

The fiscal 2026 10-K states 'The strength of our competitive positions in many of our existing markets is primarily due to our leading technology', and frames process control as 'an essential enabler' of the yield ramp in fabs the filing says now cost 'well above $10 billion'.

来源：sec.gov

The 10-K grounds the advantage in the cost of requalification, not in scale or patents: a customer that has qualified a competitor's tool is hard to win, and conversely Lam's own qualified positions persist for that application and node. The same section adds that the company must keep serving 'our installed base of customers through the delivery of high-quality and cost-efficient spare parts', naming the installed base as the asset being defended.

来源：sec.gov

The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power."

来源：sec.gov

The 10-K reports over 9,100 active patents and over 3,600 pending applications with terms running through 2045, alongside proprietary process-control software (Klarity, I-PAT, aiSIGHT) that turns inspection and metrology data into yield learning.

来源：sec.gov

The 10-K claims position but not primacy: 'We believe we are in a strong position with our leadership and expertise in deposition, etch, and clean markets.' The same document names Applied Materials as primary competitor in deposition and Applied Materials, Hitachi and Tokyo Electron as primary competitors in etch, which is a shared-leadership structure rather than a clear single leader.

来源：sec.gov

The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date."

来源：sec.gov

The 10-K opens by describing KLA as a supplier of 'industry-leading equipment and services' and attributes its competitive positions 'in many of our existing markets' primarily to leading technology; named competitors are Applied Materials, ASML, Hitachi High-Tech, Lasertec and Onto Innovation.

来源：sec.gov

Real but bounded, and the filing is explicit that the recent gain was mix rather than price. Gross margin as a percent of total revenue rose 180 basis points to 50.5% in fiscal 2026 from 48.7% in fiscal 2025 (gross margin of 11,725,308 thousand dollars on revenue of 23,232,690 thousand, against 8,979,059 on 18,435,591; 7,052,791 on 14,905,386 in fiscal 2024), and the MD&A attributes that: 'Gross margin as a percentage of revenue increased in fiscal year 2026 compared to fiscal year 2025 largely due to favorable customer mix, partially offset by aluminum and steel tariff-related spend.' Against it, the same filing says manufacturers evaluate suppliers on 'overall cost of ownership', that the spares business competes with third-party spare parts providers, and that the customer list is a handful of very large buyers (Micron, Samsung, SK hynix and TSMC named as the most significant customers).

来源：sec.gov

Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries."

来源：sec.gov

Services were approximately 23% of fiscal 2026 total revenues on an installed base that recurs, backlog nearly doubled to $12.57 billion, and SEC-reported net income was 35.6% of revenue in fiscal 2026 with operating income at 41.2% of revenue in fiscal 2025.

来源：sec.gov

Upstream wafer-fabrication-equipment supplier; the 10-K names Micron, Samsung, SK hynix and TSMC as its most significant customers across FY2024-FY2026, so Lam sits one step above the memory and foundry capacity that AI compute depends on.

A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish.

Sits beside the process steps rather than in them — it measures and inspects what deposition, etch and lithography produce, and TSMC alone exceeded 10% of revenue in each of the last three fiscal years.

• Clean systems (EOS, DV-Prime, Da Vinci, SP Series, Coronus families) 挑战者 · 中等 来源：sec.gov
• Customer Support Business Group (spares, upgrades, service, Reliant) 领先 · 中等 来源：sec.gov
• Deposition systems (ALTUS, SABRE, VECTOR, Striker families) 前三 · 深 来源：sec.gov
• Etch systems (Kiyo, Flex, Vantex, Syndion, Argos families) 前三 · 深 来源：sec.gov

• Intismeran autogene (mRNA-4157) 未知 · 中等 来源：sec.gov
• Spikevax 前三 · 中等 来源：sec.gov
• mNEXSPIKE 前三 · 中等 来源：sec.gov
• mRESVIA 挑战者 · 中等 来源：sec.gov
• mRNA-1010 seasonal influenza vaccine 未知 · 中等 来源：sec.gov

• Metrology (Archer overlay, SpectraFilm, SpectraShape, Therma-Probe) 前三 · 深 来源：sec.gov
• PCB and Component Inspection (Orbotech direct imaging, ICOS) 未知 · 中等 来源：sec.gov
• Reticle and mask inspection (Teron, TeraScan, LMS IPRO) 前三 · 深 来源：sec.gov
• Semiconductor process-control software (Klarity, I-PAT, aiSIGHT, 5D Analyzer) 未知 · 中等 来源：sec.gov
• Specialty Semiconductor Process (SPTS etch, deposition and plasma dicing) 细分市场 · 中等 来源：sec.gov
• Wafer defect inspection and review (Surfscan, Puma, eSixx, eDR7xxx, Voyager) 领先 · 深 来源：sec.gov

编辑先验，未经回测。

查看它究竟如何投票 →

编辑先验，未经回测。

查看它究竟如何投票 →

编辑先验，未经回测。

查看它究竟如何投票 →